Biotech Startups

Shared-X operates multiple subsidiaries focused on agribusiness and food sectors, including iQBiotech (biostimulants and biopesticides), Nampi Foods (consumer packaged goods), and Bananica (regenerative agriculture and specialty crop export). The company serves food and agriculture companies globally with sustainable and innovative agricultural solutions.

1 investor

Sharp Therapeutics develops a small molecule drug platform designed to treat genetic diseases more affordably and quickly than current biologics and gene therapies. The company targets patients and payors seeking faster, scalable alternatives to existing genetic disease treatments.

1 investor

Shelfion provides microbiological testing and software solutions to food businesses for extending product shelf-life and reducing waste. The company helps food manufacturers optimize food safety and sustainability through science-backed insights and test kits.

1 investor

Shift Bioscience develops siRNA therapeutics for cell rejuvenation, using a target identification platform that has identified an anti-fibrotic candidate initially aimed at liver fibrosis. The company works in the aging and longevity biotech field, having discovered novel aging targets linked to disease states.

1 investor

A psychedelics research organization that discovers new psychoactive substances and develops compounds and delivery systems for therapeutic use, continuing the work of Dr. Alexander "Sasha" Shulgin. It also operates as an educational organization in the field of psychedelics.

1 investor

Shuwen Biotech develops molecular and immunodiagnostic products for women's health, including breast cancer subtyping kits, nucleic acid extraction systems, and point-of-care tests for pregnancy complications. The company serves healthcare providers and pharmaceutical clients in clinical diagnostics and personalized medicine.

1 investor

Siamab Therapeutics is a biopharmaceutical company developing therapeutic antibodies that target tumor-associated carbohydrate antigens (glycans) found on solid tumors such as ovarian, pancreatic, prostate, colon, and breast cancers. Its technology platform, based on glycobiology research licensed from UCSD, discovers highly specific anti-TACA antibodies intended to kill cancer cells and re-engage the immune system.

1 investor

Sidefarma is a pharmaceutical manufacturer specializing in the production of solid, semi-solid, and liquid pharmaceutical forms and the commercialization of pharmaceutical products across Europe, Africa, Latin America, and Asia.

1 investor

Sierra Labs provides software to automate compliance and quality management processes for life science teams, aiming to reduce the cost and effort of meeting regulatory standards. It focuses on integrating quality management with technology and building compliance programs in regulated environments.

1 investor

1 investor

SignaCor is a clinical-stage biotech company developing Cardiaza, a first-in-class injectable epigenetic (DNA methylation inhibiting) therapy for symptomatic hypertrophic cardiomyopathy that targets underlying disease mechanisms such as cardiac fibrosis rather than only symptoms. Spun out of Queen's University Belfast, the company focuses on therapeutics for cardiac disease.

1 investor

Signature Diagnostics develops noninvasive diagnostic and screening tools, including noninvasive prenatal screening (NIPS) and pharmacogenomic (PGx) testing, based on genomics research into women's reproductive and organ health. It operates SDxLabs, a CLIA-certified clinical lab offering these testing services.

1 investor

Signet Therapeutics develops targeted cancer drugs using cancer organoid models combined with artificial intelligence. The company focuses on discovering novel therapies for cancers that currently lack effective treatment options.

1 investor

Silicodata is a pharmaceutical company composed of professionals with over 25 years of industry experience, focused on rethinking how medicine is manufactured.

1 investor

SilicoLife uses AI and biological technology to produce pure, sustainable ingredients for industrial applications. The company focuses on making ingredient production more efficient, ethical, and accessible.

1 investor

Silverspurt develops a peptide amphiphile micelle platform for precise, tissue-targeted delivery of small-molecule drugs and genetic therapeutics, reducing systemic toxicity and off-target effects. The platform is designed to improve therapeutic efficacy and patient compliance across multiple therapeutic modalities.

1 investor

Simbryo Technologies is a biotech company that creates endometrial organoids from a patient's own stem cells using a routine biopsy, offering functional diagnostic tests of the uterine lining to assess and optimize endometrial fertility. Working with research institutions and fertility clinics, it uses organoid medicine and AI to give patients and physicians insights aimed at improving IVF success rates and to serve as a test bed for new fertility treatments.

1 investor

Simplycare Bio (심플리케어바이오) operates a research and development center along with corporate offices in South Korea. The available page content does not describe the company's specific products or services beyond its bio/care sector name and contact details.

1 investor

Sindri Materials develops a scalable production process for ultra-high-quality monolayer graphene with low contamination and defects. Its initial application is graphene support grids for cryo-electron microscopy used in drug discovery, vaccine development, and disease research, with longer-term aims in electronics, energy storage, and structural materials.

1 investor

Singletto develops Oxafence Active Protection™, a materials-applied antimicrobial technology integrated into protective materials such as masks, using photodynamic approaches to enable active microbial inactivation during use. The company licenses its platform technology to healthcare, operational, and emerging markets where traditional antimicrobial solutions have proven limited.

1 investor

Sinntaxis is a pharmaceutical company developing mGluR5 negative allosteric modulators as a drug therapy to restore brain function and support recovery after stroke and brain injury. Spun out of Lund University, it runs a preclinical discovery platform for stroke recovery research and licensed IP on this treatment approach.

1 investor

SiNON Nano Sciences develops carbon nanoparticles for therapeutic and diagnostic applications, including targeted drug delivery, fluorescent bio-imaging, and treatments for oncology, diabetes, and cardiology.

1 investor

Sinotau develops radiopharmaceutical products, including diagnostic imaging agents for early detection of Alzheimer's disease. The company operates in the radiopharmaceutical sector in China, serving medical institutions and hospitals.

1 investor

Sirona Medical Technologies develops combined focal mapping and ablation catheters that deliver Pulsed Field or Radio Frequency energy to treat cardiac arrhythmias. The company operates in the cardiac electrophysiology segment of medical devices, serving physicians who diagnose and treat cardiac electrophysiology disorders.

1 investor